PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY. (23rd June 2022) - Raffoux, E.; De Botton, S.; Ades, L.; Carré, M.; Cluzeau, T.; Saillard, C.; Heiblig, M.; Beckerich, F.; Gastaud, L.; Dupuis, A.; Richez, U.; Dumas, P.-Y.